Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment

Opinion
Video

A expert cardiologist delves into the insights gained from clinical trials assessing Cardiac Myosin inhibitors (CMIs) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), with a particular focus on the EXPLORER-HCM trial, which investigated the efficacy and safety of mavacamten in managing oHCM.

Related Videos
Video 3 -  4 KOLs are featured in, "Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management"
Video 3 -  4 KOLs are featured in, "HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading"
© 2024 MJH Life Sciences

All rights reserved.